Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
123,940
result(s) for
"Melanoma"
Sort by:
Correction: PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice
[This corrects the article DOI: 10.1371/journal.pone.0228339.].
Journal Article
The neuroscientist who lost her mind : my tale of madness and recovery
As a deadly cancer spread inside her brain, neuroscientist Barbara Lipska was plunged into madness--only to miraculously survive with her memories intact. In the tradition of \"My Stroke of Insight\" and \"Brain on Fire,\" this memoir recounts her ordeal and explains its unforgettable lessons about the brain and mind.
Book
Author Correction: From genes to drugs: targeted strategies for melanoma
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Journal Article
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
In the version of this article originally published, there was an error in Fig. 1. In the neoadjuvant phase column, the n values for arms A and B were both reported to be 20. The n values for arms A and B were actually 12 and 11, respectively. Also, the URL underlying the accession code in the data availability section was incorrect. The URL was originally https://www.ebi.ac.uk/ega/studies/EGAS00001002698. It should have been https://www.ebi.ac.uk/ega/studies/EGAS00001003178. The errors have been corrected in the print, HTML and PDF versions of this article.
Journal Article
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
In the version of this article originally published, there was an error in Fig. 2b. RECIST ORR and pCR were both listed as 25%. RECIST ORR was actually 73%, and pCR was 45%. Also, an author's name was incorrect in the author list. Danny K. Wells should have been listed as Daniel K. Wells. The errors have been corrected in the print, HTML and PDF versions of this article.
Journal Article
256 Differences in immune-related adverse events between vulvovaginal vs. cutaneous melanoma: a retrospective cohort study
Introduction/Background Few studies to date have comprehensively examined all immune-related adverse events (irAEs) in vulvovaginal and cutaneous melanoma patients on immune checkpoint inhibitors (ICIs). Methodology We retrospectively analyzed 169 patients with advanced-stage vulvovaginal or cutaneous melanoma who received at least one dose of ICI between June 2012 to December 2018. Descriptive statistics were used to summarize the baseline characteristics, disease outcomes, and toxicity profiles. Chi-square statistical analysis was used to examine associations between irAEs and pre-existing conditions, as well as irAEs and treatment response. P-values <0.05 were considered statistically significant. Results Overall, 53.8% of patients with vulvovaginal melanoma developed irAEs, compared to a similar percentage of 51.9% for patients with cutaneous melanoma. Yet the most common types of irAEs differed between patients. The most common irAEs for patients with vulvovaginal melanoma were gastrointestinal disorders (44.4%), hypothyroidism (22.2%), and renal and urinary disorders (22.2%). On the other hand, the most common irAEs for patients with cutaneous melanoma on ICIs were gastrointestinal disorders (21.7%), cutaneous adverse events (17.9%) and pneumonitis (18.75%). Cutaneous adverse events were overall the most common irAEs, and were significantly associated with patient response to ICIs (p = 0.01). Conclusion Nuanced differences in the clinical presentation of irAEs in patients with vulvovaginal vs. cutaneous melanoma are important considerations for initiating ICIs in accordance with melanoma type. Furthermore, cutaneous adverse events were the most common irAEs overall, and were significantly associated with response to ICIs in patients with metastatic melanoma. Disclosures I have no conflicts of interest.
Journal Article
